Initial Designation. Within ninety (90) days of the Effective Date, Novartis shall designate three genes or polypeptides which shall be used for transducing MSCs for delivery of a gene and/or polypeptide and the use of such transduced MSCs shall become part of the Gene Therapy Area.
Appears in 2 contracts
Sources: Research Collaboration and License Agreement (Osiris Therapeutics Inc), Research Collaboration and License Agreement (Osiris Therapeutics Inc)